Investors & Media

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome

CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ —  Ionis Pharmaceuticals , Inc.  (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS),

Read more
You are now leaving https://www.ionispharma.com to visit